Welcome to our dedicated page for Therapeutic Solutions International news (Ticker: $TSOI), a resource for investors and traders seeking the latest updates and insights on Therapeutic Solutions International stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Therapeutic Solutions International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Therapeutic Solutions International's position in the market.
Therapeutic Solutions International (TSOI) has received a Notice of Allowance from the US Patent and Trademark Office for a patent on using T regulatory cells to enhance the efficacy of mesenchymal stem cells in treating lung inflammation. This patent covers a method to reduce lung inflammation through the administration of T regulatory cells combined with mesenchymal stem cells. The company is developing treatments for COVID-19, ARDS, COPD, and pulmonary fibrosis, all involving lung inflammation. The patent is expected to increase TSOI's value, with comparisons to successful deals in the sector, such as Regeneron-Sonoma and Quell-AstraZeneca.
Therapeutic Solutions International's pre-spin-off company, Campbell Neurosciences, appoints Raymond Oliver as Chairman of the Board to facilitate its entry into the capital markets. The company plans to distribute up to 10,000,000 shares to existing shareholders in a loyalty dividend. Campbell Neurosciences is focused on developing innovative technologies for the treatment of psychiatric diseases and suicidal propensities.